Compare Bristol-Myers Squibb Co (BMY) vs Invesco Galaxy Bitcoin ETF (BTCO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Bristol-Myers Squibb Co vs Invesco Galaxy Bitcoin ETF — how do they compare? Bristol-Myers Squibb Co trades at $57 (market cap $116.30B), while Invesco Galaxy Bitcoin ETF trades at $65. The key difference: Bristol-Myers Squibb Co pays a 4.42% dividend while Invesco Galaxy Bitcoin ETF pays none, and Bristol-Myers Squibb Co is trading nearer its 52-week high, Invesco Galaxy Bitcoin ETF nearer its low. Which is the better fit depends on your goals.
| BMY | BTCO | |
|---|---|---|
Market Cap | $116.30B | — |
Sector | Health | Crypto-linked |
52-Week High | $62.37 | $125.14 |
52-Week Low | $42.60 | $58.40 |
Enterprise Value | $152.24B | — |
Dividend Yield | 4.42% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Bristol Myers Squibb (BMY) trades at $59.34, up 3.06% today, with a bullish technical signal and consistent earnings beats. The stock shows strong profitability with a 15.01% net margin and 38.84% ROE, though debt levels have risen. Recent FDA acceptance for mezigdomide in multiple myeloma highlights pipeline progress. Analysts are mixed with a $60 consensus target, slightly above current price.
BMY offers value with a P/E of 16.62 and a safe 4.3% dividend yield, but faces patent cliff risks and pricing pressures. Earnings growth and pipeline execution are key catalysts, while high debt and competitive threats require monitoring. The stock presents a balanced opportunity for income-focused investors with moderate risk tolerance.
BTCO trades at $61.86, down 2.67% today amid mixed technical signals with a bullish overall trend but bearish moving averages. The stock faces resistance near $64-65 while finding support around $62-63. Financial ratios remain unavailable in current data, requiring deeper fundamental analysis.
The stock shows technical resilience despite recent selling pressure, with key support levels holding. Investment appeal depends on upcoming earnings clarity and institutional positioning. Primary risks include market volatility and competitive pressures in its sector.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Bristol-Myers Squibb Co
Bristol-Myers Squibb discovers, develops, and markets drugs for various therapeutic areas, such as cardiovascular, cancer, and immune disorders. A key focus for Bristol is immuno-oncology, where the firm is a leader in drug development. Unlike some of its more diversified peers, Bristol has exited several nonpharmaceutical businesses to focus on branded specialty drugs, which tend to support strong pricing power.
Read more on BMY →About Invesco Galaxy Bitcoin ETF
BTCO is a spot Bitcoin ETF that tracks the price of Bitcoin directly. It offers investors a regulated and convenient way to gain exposure to the digital currency through a traditional brokerage account without holding the asset.
Read more on BTCO →
